feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Ex-IPS officer shoots self

trending

Kannada actor's house theft

trending

Liverpool fan racially abuses Semenyo

trending

Interstellar comet wobbling jets

trending

Tata Avinya launch in 2026

trending

PSG targets Liga Portugal players

trending

Arsenal beat Crystal Palace on penalties

trending

Fenerbahce beats Besiktas

trending

Stars clash with Strikers

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Oral Wegovy Approved: Weight Loss Revolution!

Oral Wegovy Approved: Weight Loss Revolution!

24 Dec

•

Summary

  • First-ever oral GLP-1 medication for weight loss approved.
  • Wegovy pill shows 16.6% average weight loss in trials.
  • Oral version offers similar results to injectable Wegovy.
Oral Wegovy Approved: Weight Loss Revolution!

The U.S. has approved the first-ever oral GLP-1 medication for weight loss, marking a significant advancement in obesity treatment. The once-daily semaglutide pill, branded as Wegovy, aims to help individuals reduce excess body weight and lower cardiovascular risk.

Clinical trials, including the OASIS 4 program, revealed that the Wegovy pill resulted in an average weight loss of 16.6% for obese or overweight adults with comorbidities. A notable one in three participants achieved 20% or greater weight reduction, mirroring the efficacy of the injectable Wegovy with a similar safety profile.

This convenient oral option is slated for a U.S. launch in early January 2026, with further regulatory submissions in Europe and other regions. While promising, experts note potential variations in gastrointestinal absorption and compare its effectiveness to other drugs like tirzepatide, emphasizing the importance of lifestyle habits for sustained results.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new oral Wegovy pill is approved for weight loss in adults who are overweight or obese and have at least one weight-related condition.
The Wegovy pill is expected to launch in the U.S. in early January 2026.
Clinical trials showed the oral Wegovy pill achieved an average weight loss of 16.6%, similar to the injectable version.

Read more news on

Healthside-arrow

You may also like

Ozempic Knock-Offs: Are They Safe?

18 Dec • 31 reads

article image

GLP-1 Cancer Link Debunked? New Study Shocks!

9 Dec • 90 reads

article image

Muscle Metabolism Drug Offers Weight Loss Hope

8 Dec • 91 reads

article image

GLP-1s Reshape Festive Feasts and Fridges

7 Dec • 98 reads

article image

Children to Trial Novo Nordisk's Next-Gen Weight Drug

2 Dec • 105 reads

article image